Anzeige
Meldung des Tages: Diese Goldaktie startet NI-43-101 Ressourcenschätzung – jetzt kann aus der Story Substanz werden

Roche Holding Aktie News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
345,60 CHF
-13,80 CHF
-3,84%
375,67 € 17:19:18 Uhr
Depot/Watchlist
Marktkapitalisierung *
250,27 Mrd. €
Streubesitz
17,13%
KGV
25,93
Dividende
9,70 CHF
Dividendenrendite
2,89%
neu: Nachhaltigkeits-Score
48 %
Index-Zuordnung
-

Roche Holding News

03.04.25 - RiskmasterPro
Roche AG unter Druck: Warum die Deutsche Bank zum Verkauf der Aktie rät
Neueste Nachrichten von RiskMasterPro (Auszug) Im Spannungsfeld zwischen hoffnungsvollen Forschungsergebnissen und ernüchternden Analysteneinheiten steht Roche AG ...
02.04.25 - GlobeNewswire
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing ...
26.03.25 - RiskmasterPro
Roche in der Krise? Analysten warnen vor Risiken im Onkologiesektor
Die Aktienbewertung von Roche, einer der führenden Unternehmen im Bereich der Onkologie, hat einen markanten Kurswechsel hingelegt. Die US-Bank JPMorgan Chase & Co. ...
25.03.25 - GlobeNewswire
Roche Annual General Meeting 2025
Shareholders approved all proposals of the Board of Directors Severin Schwan was re-​elected as Chairman of the Board of Directors; all other Board members standing for ...
25.03.25 - GlobeNewswire
Roche Generalversammlung 2025
Alle Anträge des Verwaltungsrates genehmigt Severin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Mitgliedern des ...
17.03.25 - GlobeNewswire
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy ...
12.03.25 - GlobeNewswire
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
Agreement allows for a range of potentially best-​in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388 Collaboration will ...
07.03.25 - GlobeNewswire
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston
The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to ...
05.03.25 - GlobeNewswire
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal response benefit 1 The filing application is based on ...
02.03.25 - GlobeNewswire
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
First-​ever head-​to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-​breakers at the 2025 AAAAI Annual Meeting Xolair is the only US FDA-...
28.02.25 - GlobeNewswire
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 DLBCL—an aggressive disease with a high risk of ...
26.02.25 - RiskmasterPro
JP Morgan stuft Roche auf Underweight – Negative Aussichten für die Aktie
Neueste Nachrichten von RiskMasterPro (Auszug) Die Roche AG steht unter Druck: Nach einer aktuellen Analyse stuft die US-Bank JPMorgan die Aktie auf ‚Underweight‘ und setzt ...
23.02.25 - wallstreetONLINE Redaktion
Crash-Vorsorge: 1 krisensichere Dividenden-Aktie mit 3,3 % Rendite & 38 Jahre Dividendenwachstum
Starinvestor Warren Buffett erhöht zunehmend die Defensive. Diese Aktie erfüllt viele seiner Kriterien.Gerade wenn Aktien stetig steigen, erscheint ein größerer Rückschlag ...
21.02.25 - RiskmasterPro
Roche AG: UBS empfiehlt Kauf der Aktie
Neueste Nachrichten von RiskMasterPro (Auszug) Roche AG steht im Fokus der Anleger, nachdem die UBS die Aktie mit einer „Buy“-Einstufung und einem Kursziel von 338 Franken ...
20.02.25 - GlobeNewswire
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-​generation sequencing (NGS), which is playing a vital role in decoding complex ...
20.02.25 - RiskmasterPro
Roche unter Druck: Deutsche Bank senkt Bewertung auf „Sell“
Neueste Nachrichten von RiskMasterPro (Auszug) Ein Rückschlag für Roche: Die Deutsche Bank hat die Aktie des Pharmakonzerns auf „Sell“ herabgestuft und das Kursziel auf 265 ...
12.02.25 - GlobeNewswire
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Evrysdi is the only non-​invasive disease-​modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same ...
07.02.25 - GlobeNewswire
New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, ...
04.02.25 - GlobeNewswire
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per ...
31.01.25 - GlobeNewswire
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow. 1 ...

Newssuche

Videos

newspaper
27.01.26 +0,22%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »